Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Sali RCTsofosbuvirlopinavir/ritonavirCOVID 19 hospitalizedhigh
22/32 inconclusive
    Nojomi
          IRCT20180725040596N2    		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID 19 hospitalizedsome concern
    		50/50 inconclusive
      Nojomi
              IRCT20180725040596N2      		 RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
      		50/50 inconclusive

        COVID 19 all comers meta-analysis

        Chang Chen et al.
                  ChiCTR2000030254        		 RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
        		120/120 inconclusive
        • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
        jRCTs041190120
                  jRCTs041190120        		 RCTfavipiravir favipiravir COVID 19 all comershigh
        		44/45 inconclusive
        • inconclusive 42 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias

        COVID-19 mild to moderate meta-analysis

        Babalola RCTivermectinlopinavir/ritonavirCOVID-19 mild to moderatehigh
        		21/20 no results
          Solaymani-Dodaran
                      IRCT20200318046812N1          		 RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
          		193/187 inconclusive
            ELACOI (Lopinavir/ritonavir)
                          NCT04252885            		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
            		35/34 inconclusive
            • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
            • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
            GS-US-540-5773 (Goldman)
                          NCT04292899            		 RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
            		200/197 suggested
            • suggested 53 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
            Hung et al.
                          NCT04276688            		 RCTlopinavir/ritonavir, ribavirin and interferon beta-1blopinavir/ritonavirCOVID-19 mild to moderatesome concern
            		86/41 conclusif
            • demonstrated 3.4-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 2.9-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
            Ren
                          ChiCTR2000029853            		 RCTazvudineantiviral and associated therapyCOVID-19 mild to moderatesome concern
            		10/10 suggested
            • suggested 27.5-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias

            COVID-19 severe or critically meta-analysis

            Galan
                          RBR-8h7q82            		 RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
            		53/115 suggested
            • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
            Galan
                          RBR-8h7q82            		 RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
            		53/115 suggested
            • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
            4 studies excluded by filtering options (0 RCT / 4 OBS)

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

             

            - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons